Report topline proteinuria results from the PROTECT Study of sparsentan in IgA nephropathy
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Sep 2021
- Delivered
- August 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Phase 3 PROTECT Study of sparsentan in IgA nephropathy (IgAN) remains on-track to report topline data from the 36-week proteinuria analysis in the third quarter of 2021”
What we found
Evidence strength A What the grades mean
Filings state the company announced positive topline PROTECT interim proteinuria results in August 2021, within the third quarter 2021 deadline.
-
A Travere Therapeutics, Inc. 8-K filed 2021-10-28
“In August 2021, the Company announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgAN.” ✓ confirmed on the page
-
A Travere Therapeutics, Inc. 10-Q filed 2021-10-29
“In August 2021, we announced positive topline interim results from the ongoing Phase 3 PROTECT Study.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Topline 36-week proteinuria data from PROTECT Study
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Travere Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TVTX-024878 · Corrections policy